StoneX Group’s Bright Minds Biosciences DRUG Stock Holding History

StoneX Group’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,039	Closed	-$7.54K	–	505
2022 Q4	$7.54K	Buy	+2,039	New	+$10.1K	﹤0.01%	470

Other funds holding DRUG

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QFA

Quattro Financial Advisors The Woodlands, Texas $468M AUM 13.49% 1-Year Est. Return

CCA

Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

StoneX Group's DRUG Position: Q1 2023 in Review

StoneX Group sold out of Bright Minds Biosciences (DRUG) in Q1 2023, closing a stake of 2,039 shares — an estimated $7.54K sold.

StoneX Group first reported a position in DRUG in Q4 2022 and held it in 1 quarter. The position peaked at $7.54K in Q4 2022. 9 funds tracked by Wall St. Rank hold DRUG as of Q1 2023.

StoneX Group reported no remaining Bright Minds Biosciences position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 2,039 Bright Minds Biosciences shares in Q1 2023, an estimated $7.54K.
StoneX Group first reported a position in Bright Minds Biosciences in Q4 2022 and held it in 1 quarter.
StoneX Group's Bright Minds Biosciences position peaked at $7.54K in Q4 2022.
9 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.